13 Most Undervalued Pharma Stocks To Buy According To Analysts

Published on October 30, 2023 at 4:35 pm by Ramish Cheema in Hedge Funds, News

In this piece, we will take a look at the 13 most undervalued pharmaceutical stocks to buy according to analysts. If you want to skip our overview of the pharma industry, then check out 5 Most Undervalued Pharma Stocks To Buy.

The pharmaceutical industry is one of the biggest in the world and one that has operations in nearly every corner of the globe. It is also one of the most diverse segments in terms of products, as its offerings range from generic drugs that can be made by any company willing to foot the production bill and high end genomic treatments that seek to rework the very building blocks of the human body.

These factors make the global pharmaceutical segment quite lucrative. According to market research estimates, the industry was worth $1.25 trillion in 2021, making it stand shoulder to shoulder with other big industries such as crude oil and real estate despite the fact that pharma products are often quite cheaper than a barrel of oil or a house. From the $1.25 trillion valuation, the sector is expected to grow at a compounded annual growth rate (CAGR) of 8% between 2021 and 2025 for an estimated value of $1.7 trillion by the end of the forecast period. Just like oil and real estate, the pharmaceutical industry also requires large capital investments in new products; however, unlike oil and real estate which often have customers ready to scoop up the end product, pharmaceutical players often have to make a gamble and invest the money before they can secure a guaranteed market for their products.

These high research costs run into billions of dollars, with a research report from 2014 suggesting that it takes $2.5 billion on average per drug to see through its journey from the mind of a researcher into the body of a patient. Cumulatively, the Congressional Budget Office (CBO) estimates that the top drug companies spent more than $83 billion in research and development in 2019, which sits right at par with the costs to set up a new chip manufacturing plant – one of the most capitally intensive facilities in the world. For more investment and other details about the pharmaceutical industry, you can check out Top 20 Most Profitable Pharmaceutical Companies In The World.

Naturally, these sizeable investments and lucrative values should lead to the pharmaceutical companies themselves raking in billions of dollars in profit every year. After all, no one spends billions of dollars without expecting to make multiples in revenue in return. Well, we took a look at 25 Biggest Pharmaceutical Companies in the World in terms of market capitalization and discovered that the range for their trailing twelve month revenue as of March 2023 started at $8.7 billion for the Japanese drug company Daiichi Sankyo, and ended at a whopping $100.3 billion for the U.S. pharma giant Pfizer Inc. (NYSE:PFE). Lagging Pfizer were Johnson & Johnson (NYSE:JNJ) and Roche Group who had raked in $94.9 billion and $68.5 billion, respectively.

Fast forward to October 2023, and right now it’s earnings season. Firms of all sizes are due to report their financial reports soon, and these come at a time when analysts are hungry for any and all data that can provide clues about the current state of the American economy. The economic state is more important now than perhaps ever since it holds the key to determining when the Federal Reserve will start to cut interest rates and give businesses, investors, and consumers some breathing room.

However, most pharma firms are yet to start their earnings cycle, but their performance in fiscal year 2022 has been quite impressive. According to data gathered by Accountable, the top five pharmaceutical firms in America grew their revenue by $8.8 billion in FY 2022. This hefty revenue growth also saw investors rewarded with hefty stock buybacks and dividend payouts, as these grew by $4.4 billion and $2.5 billion during the same time period, respectively. Yet, this growth might be slowing down as the coronavirus pandemic recedes and vaccine sales drop. At least that’s what the message was from Pfizer in October as the firm cut its 2023 revenue guidance by $9 billion on the top end for a 13% reduction that is also accompanied by $3.5 billion in cost cuts. On a positive note, JNJ’s latest quarterly results saw it beat analyst EPS and revenue estimates, as it saw its skin cancer and immune system disorder drugs perform well and make up for dropping sales of the COVID vaccine.

So, as the industry recovers from its coronavirus boom and the economy remains a tricky creature, we decided to take a look at some undervalued pharma stocks out which the most notable ones are Perrigo Company plc (NYSE:PRGO), Viatris Inc. (NASDAQ:VTRS), and Organon & Co. (NYSE:OGN).

A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. Editorial photo for a financial news article. 8k. –ar 16:9

Our Methodology

To make our list of undervalued pharmaceutical stocks, we ranked the 26 constituents of the VanEck Vectors Pharmaceutical ETF by the percentage upside of their average share price target over the current trading price. Out of these, the top 13 stocks with the highest upside were picked as the most undervalued pharma stocks.

13 Most Undervalued Pharma Stocks To Buy According To Analysts

13. Sanofi (NASDAQ:SNY)

Share Price Upside: 20%

Sanofi (NASDAQ:SNY) is a French pharma company that sells treatments for heart diseases, cancer, and other ailments. It marks a strong start to our list as the shares are rated Strong Buy on average. On the earnings side, Sanofi (NASDAQ:SNY) is struggling as of late since it has missed analysts EPS estimates in three of its four latest quarters.

30 out of the 910 hedge funds tracked by Insider Monkey were Sanofi (NASDAQ:SNY)’s investors as of Q2 2023. Ken Fisher’s Fisher Asset Management owns the largest stake among these, which is worth $698 million and comes via 12.9 million shares.

Just like Viatris Inc. (NASDAQ:VTRS), Perrigo Company plc (NYSE:PRGO), and Organon & Co. (NYSE:OGN), Sanofi (NASDAQ:SNY) is a top undervalued stock that hedge funds are piling into.

12. AstraZeneca PLC (NASDAQ:AZN)

Share Price Upside: 20%

AstraZeneca PLC (NASDAQ:AZN) is a British firm with treatments for kidney problems, respiratory illnesses, and other diseases. The firm scored an important win in October when the FDA approved its lung cancer drug for review.

By the end of this year’s second quarter, 41 out of the 910 hedge funds polled by Insider Monkey were the firm’s shareholders. AstraZeneca PLC (NASDAQ:AZN)’s biggest investor in our database is Rajiv Jain’s GQG Partners through its $1.5 billion stake.

11. Merck & Co., Inc. (NYSE:MRK)

Share Price Upside: 20%

Merck & Co., Inc. (NYSE:MRK) is a global pharmaceutical giant that sells drugs for both humans and animals. While its shares are rated Buy on average, the company has beaten analyst EPS estimates in all four of its latest quarters and analysts have penned in a $20 upside based on the average share price target.

As of June 2023, 78 among the 910 hedge funds part of Insider Monkey’s database had bought and owned Merck & Co., Inc. (NYSE:MRK)’s shares. Ken Fisher’s Fisher Asset Management is the firm’s largest shareholder out of these as it owns $1.4 billion worth of shares.

10. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Share Price Upside: 21%

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is an Israeli firm that is one of the oldest companies in the world since it was set up in 1901. The firm faced a setback in September when a U.S. judge overturned an earlier ruling that would have awarded Teva Pharmaceutical Industries Limited (NYSE:TEVA) $176 million in a patent infringement lawsuit.

After digging through 910 hedge fund holdings for their investments during 2023’s second quarter, Insider Monkey discovered 42 Teva Pharmaceutical Industries Limited (NYSE:TEVA) shareholders. Out of these, David Rosen’s Rubric Capital Management owns the largest stake which is worth $140 million.

9. Bristol-Myers Squibb Company (NYSE:BMY)

Share Price Upside: 26%

Bristol-Myers Squibb Company (NYSE:BMY) was set up in 1887 and it develops treatments for serious diseases such as thalassemia and cancer. Its cancer drug Opdivo was approved by the FDA for use by children and adults with skin cancer.

By the end of this year’s June quarter, 66 out of the 910 hedge funds polled by Insider Monkey had held a stake in the firm. Bristol-Myers Squibb Company (NYSE:BMY)’s biggest shareholder among these is Richard S. Pzena’s Pzena Investment Management as it owns 4.3 million shares that are worth $276 million.

8. Bausch Health Companies Inc. (NYSE:BHC)

Share Price Upside: 28%

Bausch Health Companies Inc. (NYSE:BHC) is a Canadian firm that sells pharma and eye care products. Its eye care subsidiary expanded its treatment portfolio in September 2023 by acquiring a range of eye drops for dry eye disease.

Insider Monkey’s Q2 2023 survey covering 910 hedge funds revealed that 37 were Bausch Health Companies Inc. (NYSE:BHC)’s shareholders. Carl Icahn’s Icahn Capital LP is the biggest investor among these since it has invested $277 million in the pharma company.

7. Zoetis Inc. (NYSE:ZTS)

Share Price Upside: 28%

Zoetis Inc. (NYSE:ZTS) is a pure play animal pharmaceutical company that sells medicines for cattle, poultry, fish, and other animals. Seems like Wall Street is quite bullish about the animal health sector, as its shares are rated Strong Buy on average and analysts have set a $223 average share price target.

By the end of June 2023, 65 out of the 910 hedge funds polled by Insider Monkey had bought the firm’s shares. Zoetis Inc. (NYSE:ZTS)’s largest hedge fund shareholder is William Von Mueffling’s Cantillon Capital Management due to its $251 million stake.

6. Pfizer Inc. (NYSE:PFE)

Share Price Upside: 29%

Pfizer Inc. (NYSE:PFE) is one of the biggest pharmaceutical firms in the world. As it heads to its third quarter results, the firm had some troubling news for investors as it cut down 2023 revenue estimates by 13%.

73 out of the 910 hedge funds surveyed by Insider Monkey had held a stake in Pfizer Inc. (NYSE:PFE) as of Q2 2023. Jim Simons’ Renaissance Technologies owns the largest stake among these since it owns 8.4 million shares that are worth $308 million.

Perrigo Company plc (NYSE:PRGO), Pfizer Inc. (NYSE:PFE), Viatris Inc. (NASDAQ:VTRS), and Organon & Co. (NYSE:OGN) are some undervalued pharma stocks on the hedge fund radar.

Click here to continue reading and check out 5 Most Undervalued Pharma Stocks To Buy.

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

AI is eating the world—and the machines behind it are ravenous.

Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink.

Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and building the digital future. But there’s one urgent question few are asking:

Where will all of that energy come from?

AI is the most electricity-hungry technology ever invented. Each data center powering large language models like ChatGPT consumes as much energy as a small city. And it’s about to get worse.

Even Sam Altman, the founder of OpenAI, issued a stark warning:

“The future of AI depends on an energy breakthrough.”

Elon Musk was even more blunt:

“AI will run out of electricity by next year.”

As the world chases faster, smarter machines, a hidden crisis is emerging behind the scenes. Power grids are strained. Electricity prices are rising. Utilities are scrambling to expand capacity.

And that’s where the real opportunity lies…

One little-known company—almost entirely overlooked by most AI investors—could be the ultimate backdoor play. It’s not a chipmaker. It’s not a cloud platform. But it might be the most important AI stock in the US owns critical energy infrastructure assets positioned to feed the coming AI energy spike.

As demand from AI data centers explodes, this company is gearing up to profit from the most valuable commodity in the digital age: electricity.

The “Toll Booth” Operator of the AI Energy Boom

It owns critical nuclear energy infrastructure assets, positioning it at the heart of America’s next-generation power strategy.
It’s one of the only global companies capable of executing large-scale, complex EPC (engineering, procurement, and construction) projects across oil, gas, renewable fuels, and industrial infrastructure.
It plays a pivotal role in U.S. LNG exportation—a sector about to explode under President Trump’s renewed “America First” energy doctrine.

Trump has made it clear: Europe and U.S. allies must buy American LNG.

And our company sits in the toll booth—collecting fees on every drop exported.

But that’s not all…

As Trump’s proposed tariffs push American manufacturers to bring their operations back home, this company will be first in line to rebuild, retrofit, and reengineer those facilities.

AI. Energy. Tariffs. Onshoring. This One Company Ties It All Together.

While the world is distracted by flashy AI tickers, a few smart investors are quietly scooping up shares of the one company powering it all from behind the scenes.

AI needs energy. Energy needs infrastructure.

And infrastructure needs a builder with experience, scale, and execution.

This company has its finger in every pie—and Wall Street is just starting to notice.

Wall Street is noticing this company also because it is quietly riding all of these tailwinds—without the sky-high valuation.

While most energy and utility firms are buried under mountains of debt and coughing up hefty interest payments just to appease bondholders…

This company is completely debt-free.

In fact, it’s sitting on a war chest of cash—equal to nearly one-third of its entire market cap.

It also owns a huge equity stake in another red-hot AI play, giving investors indirect exposure to multiple AI growth engines without paying a premium.

And here’s what the smart money has started whispering…

The Hedge Fund Secret That’s Starting to Leak Out

This stock is so off-the-radar, so absurdly undervalued, that some of the most secretive hedge fund managers in the world have begun pitching it at closed-door investment summits.

They’re sharing it quietly, away from the cameras, to rooms full of ultra-wealthy clients.

Why? Because excluding cash and investments, this company is trading at less than 7 times earnings.

And that’s for a business tied to:

The AI infrastructure supercycle
The onshoring boom driven by Trump-era tariffs
A surge in U.S. LNG exports
And a unique footprint in nuclear energy—the future of clean, reliable power

You simply won’t find another AI and energy stock this cheap… with this much upside.

This isn’t a hype stock. It’s not riding on hope.

It’s delivering real cash flows, owns critical infrastructure, and holds stakes in other major growth stories.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 100+% Return within 12 to 24 months.

We’re now offering month-to-month subscriptions with no commitments.

For a ridiculously low price of just $9.99 per month, you can unlock our in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $9.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

Insider Monkey Ads

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…

Insider Monkey Ads

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

13 Most Undervalued Pharma Stocks To Buy According To Analysts

Published on October 30, 2023 at 4:35 pm by Ramish Cheema in Hedge Funds, News

13 Most Undervalued Pharma Stocks To Buy According To Analysts

13. Sanofi (NASDAQ:SNY)

12. AstraZeneca PLC (NASDAQ:AZN)

11. Merck & Co., Inc. (NYSE:MRK)

10. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

9. Bristol-Myers Squibb Company (NYSE:BMY)

8. Bausch Health Companies Inc. (NYSE:BHC)

7. Zoetis Inc. (NYSE:ZTS)

6. Pfizer Inc. (NYSE:PFE)

AI, Tariffs, Nuclear Power: One Undervalued Stock Connects ALL the Dots (Before It Explodes!)

Published on June 23, 2025 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

A New Dawn is Coming to U.S. Stocks

Published on June 13, 2025 at by Insider Monkey Staff